Show simple item record

dc.contributor.authorBulur, Işıl
dc.contributor.authorBülbül Başkan, Emel
dc.contributor.authorÖzdemir, Mustafa
dc.contributor.authorBalevi, Ali
dc.contributor.authorKocatürk Göncü, Emek
dc.contributor.authorKıvanç Altunay, İlknur
dc.contributor.authorGönül, Müzeyyen
dc.contributor.authorErgin, Can
dc.contributor.authorErtam, İlgen
dc.contributor.authorKaya Erdoǧan, Hilal
dc.contributor.authorBilgin, Muzaffer
dc.contributor.authorErdem, Mustafa Teoman
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:17Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:17Z
dc.date.issued2018en_US
dc.identifier.citationBulur, I., Bülbül Başkan, E., Özdemir, M., Balevi, A., Kocatürk Göncü, E., Kıvanç Altunay, İ. ... Erdem, M. T. (2018). The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey. Acta Dermatovenerologica Alpina, Pannonica et Adriatica, 27(3), 121-126. https://dx.doi.org/10.15570/actaapa.2018.25en_US
dc.identifier.issn1318-4458
dc.identifier.issn1581-2979
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1120
dc.identifier.urihttps://dx.doi.org/10.15570/actaapa.2018.25
dc.description.abstractIntroduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months. Results: The mean weekly urticarial activity score (UAS7) after omalizumab treatment improved significantly compared to the pretreatment score (p <0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab’s treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 ± 6.15 before treatment and decreased to 3.55 ± 3.60 6 months after treatment (p <0.001). No side effects were reported in 89.4% (118) of the patients. Conclusion: This study showed that UAS7 decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data.en_US
dc.language.isoengen_US
dc.publisherSlovenian Medical Societyen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Spontaneous Urticariaen_US
dc.subjectDermatology Life Qualityen_US
dc.subjectOmalizumaben_US
dc.subjectSide Effecten_US
dc.subjectUAS7en_US
dc.titleThe efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkeyen_US
dc.typearticleen_US
dc.relation.journalActa Dermatovenerologica Alpina, Pannonica et Adriaticaen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıklar Ana Bilim Dalıen_US
dc.authorid0000-0002-7022-913Xen_US
dc.authorid0000-0001-5057-0405en_US
dc.identifier.volume27en_US
dc.identifier.issue3en_US
dc.identifier.startpage121en_US
dc.identifier.endpage126en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.15570/actaapa.2018.25en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record